Functional aspects of root architecture and mycorrhizal inoculation with respect to nutrient uptake capacity

ACESSO via B-on: http://dx.doi.org/10.1007/s00572-003-0254-5The aim of this research was to investigate theeffect of arbuscular mycorrhizal (AM) colonisation onroot morphology and nitrogen uptake capacity of carob(Ceratonia siliqua L.) under high and low nutrientconditions. The experimental design was a factorialarrangement of presence/absence of mycorrhizal fungusinoculation (Glomus intraradices) and high/low nutrientstatus. Percent AM colonisation, nitrate and ammoniumuptake capacity, and nitrogen and phosphorus contentswere determined in 3-month-old seedlings. Grayscale andcolour images were used to study root morphology andtopology, and to assess the relation between rootpigmentation and physiological activities. AM colonisationlead to a higher allocation of biomass to white andyellow parts of the root. Inorganic nitrogen uptakecapacity per unit root length and nitrogen content weregreatest in AM colonised plants grown under low nutrientconditions. A better match was found between plantnitrogen content and biomass accumulation, than betweenplant phosphorus content and biomass accumulation. It issuggested that the increase in nutrient uptake capacity ofAM colonised roots is dependent both on changes in rootmorphology and physiological uptake potential. Thisstudy contributes to an understanding of the role of AMfungi and root morphology in plant nutrient uptake andshows that AM colonisation improves the nitrogennutrition of plants, mainly when growing at low levelsof nutrients

Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system

Neurofibromatosis type 2 (NF2), tuberous sclerosis (TS), and von Hippel-Lindau disease (VHL) are tumor suppressor syndromes characterized by multiple benign tumors of the peripheral and central nervous system.1 These tumors may lead to an enhanced obstetric risk in female patients, but it is currently unknown whether women with NF2, TS, or VHL experience increased rates of adverse pregnancy outcomes. Current data consist primarily of case series, even the largest of which may lack power because of the small sample sizes

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

Background Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated with bilateral vestibular schwannomas, benign tumors that arise from the eighth cranial nerve. There is no medical treatment for such tumors. Methods We determined the expression pattern of vascular endothelial growth factor (VEGF) and three of its receptors, VEGFR-2, neuropilin-1, and neuropilin-2, in paraffinembedded samples from 21 vestibular schwannomas associated with neurofibromatosis type 2 and from 22 sporadic schwannomas. Ten consecutive patients with neurofibromatosis type 2 and progressive vestibular schwannomas who were not candidates for standard treatment were treated with bevacizumab, an anti-VEGF monoclonal antibody. An imaging response was defined as a decrease of at least 20% in tumor volume, as compared with baseline. A hearing response was defined as a significant increase in the word-recognition score, as compared with baseline. Results VEGF was expressed in 100% of vestibular schwannomas and VEGFR-2 in 32% of tumor vessels on immunohistochemical analysis. Before treatment, the median annual volumetric growth rate for 10 index tumors was 62%. After bevacizumab treatment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up. The median best response to treatment was a volumetric reduction of 26%. Three patients were not eligible for a hearing response; of the remaining seven patients, four had a hearing response, two had stable hearing, and one had progressive hearing loss. There were 21 adverse events of grade 1 or 2. Conclusions VEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas

Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma

Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there are no standardized endpoints in NF2. We review the challenges of NF2 clinical trials and suggest possible response criteria for use in initial phase II studies. We suggest two main response criteria in such trials. Objective radiographic response is defined as a durable 20% or greater reduction in VS volume based on postcontrast T1-weighted MRI images collected with 3 mm or finer cuts through the internal auditory canal. Hearing response is defined as a statistically significant improvement in word recognition scores using 50-word recorded lists in audiology. A possible composite endpoint incorporating both radiographic response and hearing response is outlined. We emphasize pitfalls in response assessment and suggest guidelines to minimize misinterpretations of response. We also identify research goals in NF2 to facilitate future trial conduct, such as identifying the expectations for time to tumor progression and time to measurable hearing loss in untreated NF2-related VS, and the relation of both endpoints to patient prognostic factors (such as age, baseline tumor volume, and measures of disease severity). These data would facilitate future use of endpoints based on stability of tumor size and hearing, which might be more appropriate for testing certain drugs. We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents

The medical student

The Medical Student was published from 1888-1921 by the students of Boston University School of Medicine

Emergence of a unique group of necrotizing mycobacterial diseases.

Although most diseases due to pathogenic mycobacteria are caused by Mycobacterium tuberculosis, several other mycobacterial diseases-caused by M. ulcerans (Buruli ulcer), M. marinum, and M. haemophilum-have begun to emerge. We review the emergence of diseases caused by these three pathogens in the United States and around the world in the last decade. We examine the pathophysiologic similarities of the diseases (all three cause necrotizing skin lesions) and common reservoirs of infection (stagnant or slow-flowing water). Examination of the histologic and pathogenic characteristics of these mycobacteria suggests differences in the modes of transmission and pathogenesis, though no singular mechanism for either characteristic has been definitively described for any of these mycobacteria

How Does Variation in the Body Composition of Both Stimuli and Participant Modulate Self-Estimates of Men’s Body Size?

When measured in units of body mass index (BMI), how much variation in men’s self-estimates of body size is caused by i) variation in participants’ body composition and ii) variation in the apparent muscle mass and muscle tone of the stimuli being judged? To address this, we generated nine sets of male CGI bodies representing low, mid, and high muscle mass rendered at low, mid, and high muscle tone, from 18.75 to 40 BMI-hse units. BMI-hse units in this study are estimates of BMI derived from calibration equations predicting BMI from waist and hip circumference, age, sex, height, and ethnicity in the Health Survey for England databases. Forty-five healthy adult men estimated their body size using a yes-no paradigm for each combination of muscle mass/tone. We also measured participants’ body composition with Harpenden callipers and their body concerns with psychometric questionnaires. We show that stimulus variation in apparent muscle mass/tone can introduce differences up to ∼2.5 BMI-hse units in men’s self-estimates of body size. Moreover, men with the same actual BMI, but different body composition, showed up to ∼5-7 BMI-hse unit differences in self-estimates of body size. In the face of such large errors, we advocate that such judgments in men should be made instead by simultaneously manipulating both the adiposity and the muscle mass of stimuli which are appropriately calibrated for body composition, so that the participant can match the body size and shape they believe themselves to have to the stimulus they see

Sporadic hemangioblastomas are characterized by cryptic VHL inactivation

Hemangioblastomas consist of 10-20% neoplastic “stromal” cells within a vascular tumor cell mass of reactive pericytes, endothelium and lymphocytes. Familial cases of central nervous system hemangioblastoma uniformly result from mutations in the Von Hippel-Lindau (VHL) gene. In contrast, inactivation of VHL has been previously observed in only a minority of sporadic hemangioblastomas, suggesting an alternative genetic etiology. We performed deep-coverage DNA sequencing on 32 sporadic hemangioblastomas (whole exome discovery cohort n = 10, validation n = 22), followed by analysis of clonality, copy number alteration, and somatic mutation. We identified somatic mutation, loss of heterozygosity and/or deletion of VHL in 8 of 10 discovery cohort tumors. VHL inactivating events were ultimately detected in 78% (25/32) of cases. No other gene was significantly mutated. Overall, deep-coverage sequence analysis techniques uncovered VHL alterations within the neoplastic fraction of these tumors at higher frequencies than previously reported. Our findings support the central role of VHL inactivation in the molecular pathogenesis of both familial and sporadic hemangioblastomas

Rapid Intraoperative Molecular Characterization of Glioma

IMPORTANCE: Conclusive intraoperative pathologic confirmation of diffuse infiltrative glioma guides the decision to pursue definitive neurosurgical resection. Establishing the intraoperative diagnosis by histologic analysis can be difficult in low-cellularity infiltrative gliomas. Therefore, we developed a rapid and sensitive genotyping assay to detect somatic single-nucleotide variants in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1). OBSERVATIONS: This assay was applied to tissue samples from 190 patients with diffuse gliomas, including archived fixed and frozen specimens and tissue obtained intraoperatively. Results demonstrated 96% sensitivity (95% CI, 90%–99%) and 100% specificity (95% CI, 95%–100%) for World Health Organization grades II and III gliomas. In a series of live cases, glioma-defining mutations could be identified within 60 minutes, which could facilitate the diagnosis in an intraoperative timeframe. CONCLUSIONS AND RELEVANCE: The genotyping method described herein can establish the diagnosis of low-cellularity tumors like glioma and could be adapted to the point-of-care diagnosis of other lesions that are similarly defined by highly recurrent somatic mutations

BMQ

BMQ: Boston Medical Quarterly was published from 1950-1966 by the Boston University School of Medicine and the Massachusetts Memorial Hospitals